Home > Insider Trading > Filing (0001567619-21-012030)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1724344	Entasis Therapeutics Holdings Inc.	ETTX	Pharmaceutical Preparations (2834)	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1080014	Innoviva, Inc.	1350 Old Bayshore Highway Suite 400 Burlingame CA 94010		No	No	Yes	No
1842875	Innoviva Strategic Opportunities Llc	1350 Old Bayshore Highway Suite 400 Burlingame CA 94010		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-06-11	6,268,975	$2.00	10,000,000	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrants to Purchase Common Stock	Acquisiton	2021-06-11	6,268,975	$2.00	6,268,975	$2.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
10,000,000	2021-06-11	2026-06-11	No	4	P	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	18,672,897	Direct

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Warrants to Purchase Common Stock	$0.00			18,672,897	18,672,897	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
	18,672,897	18,672,897	Direct

Footnotes

As reflected in the Amendment No. 5 to Schedule 13D filed by Innoviva, Inc. ("INVA") and Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of INVA ("ISO" and together with INVA, the "Reporting Persons") with the U.S. Securities and Exchange Commission on June 11, 2021 (the "Schedule 13D/A"), in connection the closing that occurred on June 11, 2021 pursuant to a securities purchase agreement, dated as of May 3, 2021 (the "Purchase Agreement" and, such closing, the "Closing"), by and between Entasis Therapeutics Holdings Inc. (the "Issuer") and ISO, ISO acquired 6,268,975 shares of common stock of the Issuer ("Shares") and warrants to purchase an additional 6,268,975 Shares ("Warrants" and together with the Shares, the "Security") for an aggregate price of $2.00 per Security as set forth in this Form 4. ISO previously acquired 3,731,025 shares of common stock of the issuer and warrants to purchase an aggregate 3,731,025 shares of common stock of the Issuer on May 3, 2021.
(2) INVA acquired an aggregate of 18,672,897 shares of common stock of the issuer and warrants to purchase an aggregate 18,672,897 shares of common stock of the Issuer in transactions on April 22, 2020, June 11, 2020 and September 1, 2020.